This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Singh, A. Articles by Biswal, S. Search for Related Content PubMed PubMed Citation Articles by Singh, A. Articles by Biswal, S.

RNAi-Mediated Silencing of Nuclear Factor Erythroid-2–Related Factor 2 Gene Expression in Non–Small Cell Lung Cancer Inhibits Tumor Growth and Increases Efficacy of Chemotherapy

¹ Division of Toxicology, Department of Environmental Health Sciences, Bloomberg School of Public Health and ² Division of Pulmonary and Critical Care Medicine, School of Medicine, Johns Hopkins University; Departments of ³ Pathology, ⁴ Biostatistics/Oncology, and ⁵ Radiation Oncology and Molecular Radiation Sciences Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland; and ⁶ Quark Pharmaceuticals, Inc., Fremont, California

Requests for reprints: Shyam Biswal, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205. Phone: 410-955-4728; Fax: 410-955-0116; E-mail: sbiswal{at}jhsph.edu.

Key Words: Nrf2 • Keap1 • lung cancer • drug resistance • ROS • RNAi

Nuclear factor erythroid-2–related factor 2 (Nrf2) is a redox-sensitive transcription factor that regulates the expression of electrophile and xenobiotic detoxification enzymes and efflux proteins, which confer cytoprotection against oxidative stress and apoptosis in normal cells. Loss of function mutations in the Nrf2 inhibitor, Kelch-like ECH-associated protein (Keap1), results in constitutive activation of Nrf2 function in non–small cell lung cancer. In this study, we show that constitutive activation of Nrf2 in lung cancer cells promotes tumorigenicity and contributes to chemoresistance by up-regulation of glutathione, thioredoxin, and the drug efflux pathways involved in detoxification of electrophiles and broad spectrum of drugs. RNAi-mediated reduction of Nrf2 expression in lung cancer cells induces generation of reactive oxygen species, suppresses tumor growth, and results in increased sensitivity to chemotherapeutic drug–induced cell death in vitro and in vivo. Inhibiting Nrf2 expression using naked siRNA duplexes in combination with carboplatin significantly inhibits tumor growth in a subcutaneous model of lung cancer. Thus, targeting Nrf2 activity in lung cancers, particularly those with Keap1 mutations, could be a promising strategy to inhibit tumor growth and circumvent chemoresistance. [Cancer Res 2008;68(19):7975–84]

This article has been cited by other articles:

				S. Homma, Y. Ishii, Y. Morishima, T. Yamadori, Y. Matsuno, N. Haraguchi, N. Kikuchi, H. Satoh, T. Sakamoto, N. Hizawa, et al. Nrf2 Enhances Cell Proliferation and Resistance to Anticancer Drugs in Human Lung Cancer Clin. Cancer Res., May 15, 2009; 15(10): 3423 - 3432. [Abstract] [Full Text] [PDF]